SHL Telemedicine Ltd. (NASDAQ:SHLT - Get Free Report) was the target of a significant drop in short interest in April. As of April 30th, there was short interest totalling 100 shares, a drop of 92.3% from the April 15th total of 1,300 shares. Based on an average daily trading volume, of 3,800 shares, the days-to-cover ratio is presently 0.0 days.
Analyst Upgrades and Downgrades
Separately, Litchfield Hills Research reaffirmed a "buy" rating and issued a $11.00 price objective on shares of SHL Telemedicine in a report on Thursday, March 14th.
View Our Latest Research Report on SHLT
SHL Telemedicine Trading Down 0.6 %
Shares of NASDAQ SHLT traded down $0.02 during midday trading on Friday, reaching $4.07. 565 shares of the company traded hands, compared to its average volume of 2,857. SHL Telemedicine has a 52 week low of $4.06 and a 52 week high of $12.75. The stock has a 50-day moving average price of $5.69 and a 200 day moving average price of $7.26. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.30 and a quick ratio of 2.10.
About SHL Telemedicine
(
Get Free Report)
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider SHL Telemedicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SHL Telemedicine wasn't on the list.
While SHL Telemedicine currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
